| Analysis | Metabolite Name | Measured Value | Units | Treatment |
|---|---|---|---|---|
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.5698 | relative value | Control |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.5709 | relative value | Control |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.5801 | relative value | Control |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.6356 | relative value | Control |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.6426 | relative value | Control |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.6487 | relative value | WNK463 |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.6501 | relative value | Control |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.7053 | relative value | Control |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.7523 | relative value | WNK463 |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.7613 | relative value | Vehicle |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.7846 | relative value | Control |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.8210 | relative value | Vehicle |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.8309 | relative value | Control |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.8804 | relative value | Vehicle |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.8984 | relative value | WNK463 |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 0.9967 | relative value | WNK463 |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.0000 | relative value | WNK463 |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.0055 | relative value | Vehicle |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.0179 | relative value | Vehicle |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.0292 | relative value | WNK463 |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.0403 | relative value | Control |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.0475 | relative value | WNK463 |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.0861 | relative value | WNK463 |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.1382 | relative value | Vehicle |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.1503 | relative value | Vehicle |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.1656 | relative value | WNK463 |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.2312 | relative value | Vehicle |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.2574 | relative value | WNK463 |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.2661 | relative value | Vehicle |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.3664 | relative value | Vehicle |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.4617 | relative value | Vehicle |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.8336 | relative value | Vehicle |
| Reversed phase POSITIVE ION MODE | 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* | 1.8482 | relative value | Vehicle |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|